The role of stromal cells in inflammatory bone loss by Buckley, Christopher & Naylor, Amy
 
 
The role of stromal cells in inflammatory bone loss
Buckley, Christopher; Naylor, Amy
DOI:
10.1111/cei.12979
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Buckley, C & Naylor, A 2017, 'The role of stromal cells in inflammatory bone loss', Clinical & Experimental
Immunology. https://doi.org/10.1111/cei.12979
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is the peer reviewed version of the following article: Wehmeyer, C., Pap, T., Buckley, C. D. and Naylor, A. J. (2017), The role of stromal
cells in inflammatory bone loss. Clin Exp Immunol. Accepted Author Manuscript, which has been published in final form at
10.1111/cei.12979. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-
Archiving.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
 Amy J Naylor  
The role of stromal cells in inflammatory bone loss 
 Corinna Wehmeyer1, Thomas Pap2, Christopher D Buckley1,  Amy J Naylor1 
 
1Institute of Inflammation and Ageing (IIA), University of Birmingham, Queen 
Elizabeth Hospital, Birmingham B15 2WB, UK 
2Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, 
Albert-Schweitzer-Campus 1, D3, 48149, Muenster, Germany 
 
Corresponding author: 
Professor Christopher D Buckley 
Institute of Inflammation and Ageing (IIA), University of Birmingham, Queen Elizabeth 
Hospital, Birmingham B15 2WB, UK 
Direct Line:  +44 (0)121 371 3240  
E mail : c.d.buckley@bham.ac.uk 
 
Keywords:  
RA, stromal cells, bone remodelling, inflammatory cytokines, RA-FLS  
Abbreviations: 
ALP   Alkaline Phosphatase 
AP-1   Activator Protein 1 
APC    Adenomatous Polyposis Coli 
CAFs    Cancer-Associated Fibroblasts  
CamKII   Calcium sensitive enzyme calmodulin K II 
CD248   Endosialin 
CIA   Collagen-Induced Arthritis 
CK1    Casein Kinase 1  
DKK1   Dickkopf-1   
DSH   Dishevelled 
FAP1   Fibroblast Activation Protein 1  
FGF   Fibroblast Growth Factor 
Fz   Frizzled   
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1111/cei.12979
This article is protected by copyright. All rights reserved.
G6PI   Glucose-6-Phosphate-Isomerase 
GDF-8  Growth/Differentiation Factor 8, myostatin 
gp 38   Glycoprotein 38, podoplanin 
GSK3β  Glycogen synthase kinase 3β 
hTNFtg mice  human Tumour Necrosis Factor transgenic mice 
IBD   Inflammatory Bowel Disease  
IL   Interleukin 
LRP5/6            Low density lipoprotein Receptor-related Protein 5/6 
M-CSF  Macrophage-Colony-Stimulating Factor 
MMP    Matrix Metalloproteinase 
MSC   Mesenchymal Stem Cell 
NFAT   Nuclear Factor of Activated T-cells 
NF-κB   Nuclear Factor ‘kappa-light-chain-enhancer’ of activated B-cells 
OA   Osteoarthritis 
OPG   Osteoprotegerin 
PKC   Protein Kinase C 
PTH   Parathyroid Hormone 
RA    Rheumatoid Arthritis 
RA-FLS  RA Fibroblast-Like Synoviocytes 
RANK   Receptor-Activator of NF 
RANKL  Receptor-Activator of NF-κB 
Runx2   Runt-related transcription factor 2 
SCID    Severe Combined Immune-Deficient 
TGF-β  Transforming Growth Factor beta 
Th cells                   T-helper cells
TNFα   Tumour Necrosis Factor alpha 
TNFΔARE          Tumour Necrosis Factor ΔARE 
VCAM-1  Vascular Cell Adhesion Molecule 1  
Wnt   Wingless and int-1 
  
This article is protected by copyright. All rights reserved.
 Summary 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic 
inflammation, local and systemic bone loss and a lack of compensatory bone repair. 
Fibroblast-like synoviocytes (FLS) are the most abundant cells of the stroma and a 
key population in autoimmune diseases such as RA. An increasing body of evidence 
suggests that these cells play not only an important role in chronic inflammation and 
synovial hyperplasia but also impact bone remodelling. Under inflammatory 
conditions FLS release inflammatory cytokines, regulate bone destruction and 
formation and communicate with immune cells to control bone homeostasis. Other 
stromal cells such as osteoblasts and terminally differentiated osteoblasts, termed 
osteocytes, are also involved in the regulation of bone homeostasis and are 
dysregulated during inflammation. 
This review highlights our current understanding of how stromal cells influence the 
balance between bone formation and bone destruction. Increasing our understanding 
of these processes is critical to enable the development of novel therapeutic 
strategies with which to treat bone loss in RA. 
 
 
Introduction 
Rheumatoid arthritis (RA) is an immune-mediated chronic inflammatory disorder of 
synovial joints characterised by pain, swelling and progressive joint destruction. The 
synovium is present in articulated joints and serves to produce and maintain synovial 
fluid that aids joint lubrication and movement. The synovial membrane is just one to 
two cells thick in a healthy joint and is formed of macrophages, which remove debris, 
and synovial fibroblasts that produce hyaluronan and other extracellular matrix 
components of the synovial fluid. In RA the synovium becomes thickened due to an 
expansion of synovial fibroblasts as well as an infiltration of immune cells, blood 
vessels and osteoclasts all of which contribute to the swelling and stiffness 
characteristic of the disease. Activated RA fibroblast-like synoviocytes (RA-FLS) are 
the most abundant stromal cell in the inflamed synovium. These cells not only 
destroy cartilage via matrix metalloproteinase (MMP) secretion but are also able to 
destroy subchondral bone via regulation of osteoclastogenesis [1-3]. Once activated, 
RA-FLS maintain their tumour-like, aggressive behaviour even after multiple 
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passages in vitro [4] and to date there is no conclusive molecular explanation for this 
stable, persistent  activation.  
 
Besides FLS the stroma comprises a number of matrix-producing, structural cell 
types including endothelial cells, pericytes, epithelial cells and osteoblasts [5]. In the 
last few years several studies have focussed on the influence of stromal cells on 
bone remodelling. Various factors released by these cells influence the balance 
between bone-forming osteoblasts and bone-resorbing osteoclasts towards bone 
loss. This review summarizes the direct and indirect impact of stromal cells on bone 
resorption in chronic inflammatory disorders.  
  
Bone remodelling under resting conditions 
Bone remodelling depends on the tight coupling of bone formation and bone 
resorption to balance bone mass and adopt bone structure to environmental changes 
such as mechanical loading (ensure that there is no net bone change). Under 
normal, resting conditions osteoclasts are required for continuous bone remodelling 
via communication with osteoblasts. Osteoclasts create resorption lacunae, which in 
turn activate osteoblasts that fill these lacunae with new bone matrix.  
 
Osteoblasts arise from pluripotent mesenchymal stem cells (MSC). The 
differentiation of osteoblast progenitor cells into bone matrix-producing osteoblasts 
requires tight control of essential signals such as parathyroid hormone (PTH) [6] 
transforming growth factor-β (TGF-β) and fibroblast growth factor (FGF) [7, 8]. 
Furthermore, essential signalling pathways including the bone morphogenic protein 
(BMP) pathway and the canonical Wnt/β-catenin pathway regulate the expression of 
runt-related transcription factor 2 (Runx2) [9], alkaline phosphatase (ALP) [10] and 
osteoprotegerin (OPG) [11], which are all involved in osteoblast differentiation and 
metabolism.  
 
Conversely, osteoclasts are multinucleated cells derived from hematopoietic stem 
cells. Osteoclast development involves an initial differentiation step towards 
monocytes and macrophages, which is under the control of macrophage-colony-
stimulating factor (M-CSF). Following this there is a requirement for the receptor 
activator of NF-κB (RANK) and the receptor activator of NF-κB ligand (RANKL) [12]. 
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RANKL binds to its receptor RANK on the surface of pre-osteoclasts, stimulating 
macrophage/monocyte fusion and the development of active, mature osteoclasts [13, 
14]. RANKL is produced predominantly by stromal cells, specifically by osteocytes, 
osteoblasts and fibroblasts, as well as a subset of B cells [15, 16]. The RANKL decoy 
receptor OPG is also produced by stromal cells and blocks osteoclastogenesis by 
interacting with RANKL [17]. This is supported by results from mouse models 
revealing that RANKL deficiency causes osteopetrosis [18] whilst OPG deficient mice 
are osteoporotic [19]. Importantly, therefore both the main driver of 
osteoclastogenesis (RANKL) and the major inhibitor (OPG) are produced by stromal 
cells (osteoblasts and FLS) and the ratio between these two proteins is a key 
determinant of activation or inhibition of osteoclastogenesis during both normal, 
healthy bone turnover and in pathological bone destruction during inflammatory 
disease [17, 20]. 
 
Bone remodelling in RA 
In addition to the pain, swelling and associated loss of function caused by synovial 
inflammation, resorption of bone tissue is a classical characteristic of RA. Erosion 
starts very early in disease, is irreversible and accompanied by permanent functional 
impairment [21]. This process predominantly occurs at the regions where the articular 
cartilage, bone and inflamed synovium (pannus) meet with subchondral bone 
destroyed from the outside inwards by cells within the invading pannus tissue. The 
predominant bone-degrading cell within the pannus is the osteoclast [22, 23].  
 
In RA, inflammation and bone loss are closely linked processes. In this context, 
inflammatory cytokines including TNFα, IL-1β, IL-6 and IL-17 are produced by 
infiltrating macrophages and T-cells. These cytokines induce RA-FLS, osteoblasts 
and bone marrow stromal cells to express RANKL, thus promoting 
osteoclastogenesis [24-27]. RA synovial tissues express elevated RANKL mRNA and 
protein compared to patients with osteoarthritis (OA) or to RA patients with less 
active disease. This elevated level of RANKL is accompanied by diminished OPG 
expression [28-30]. Thus, the uneven quantities of OPG and RANKL within the RA 
microenvironment results in an imbalance in the osteoblast-osteoclast axis leading to 
an overall bias towards bone resorption. 
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In addition to RANKL, OPG and cytokines, stromal cells of the inflamed synovial 
tissue also express other factors, which directly influence osteoclastogenesis. One of 
these factors is myostatin (also known as GDF-8), which belongs to the TGFβ family 
and is mainly expressed in skeletal muscle. Deletion of myostatin leads to muscle 
hypertrophy [31]. In addition to its role as a negative regulator of muscle growth, 
several studies have revealed a new role for myostatin in bone homeostasis. Genetic 
deletion or antibody-mediated blockade of myostatin leads to high bone density and 
volume in a mouse model of osteotomy [32-35]. Recently, Dankbar and colleagues 
showed for the first time that myostatin is highly expressed in stromal cells of RA 
synovial tissues and that deficiency or antibody-mediated inhibition leads to an 
amelioration of arthritis in mouse models of arthritis. Functional in vitro studies 
revealed that myostatin enhances RANKL-mediated osteoclast formation by 
promoting the fusion of pre-osteoclasts, leading to enhanced bone loss [36]. 
 
In addition to encouraging osteoclast activity, inflammatory conditions inhibit the 
reparative activity of osteoblasts. Gilbert et al. [37, 38] identified that, when TNFα 
was included in pre-osteoblast cultures, osteoblast differentiation and maturation in 
vitro was arrested. Others have similarly found that osteoblast maturation markers 
such as collagen type I, alkaline phosphatase and osteocalcin are all reduced in the 
presence of TNFα [24, 39, 40] , leaving these osteoblasts unable to upregulate matrix 
mineralisation [41]. Osteoblasts cultured with serum from RA patients on Infliximab 
therapy show reduced expression of IL-6, a cytokine linked to arthritis-related bone 
loss [42]. IL-6 binds the IL-6 receptor, an interaction which induces prostaglandin E2 
synthesis, in turn reducing the ratio of OPG/RANKL expression by osteoblasts, 
thereby favouring osteoclastogenesis [43]. In addition, osteoblasts cultured with 
serum from patients treated with Infliximab show reduced expression of IL-1β [42], 
known to inhibit bone formation in vitro [44] and in vivo [45] as well as impaired 
osteoblast migration [46]. Presumably because of the factors described above, it has 
been reported that TNF blockade in RA patients corrects bone metabolism imbalance 
seen in RA [47]. 
 
In RA the local microenvironment is profoundly changed due to the influx of immune 
cells and proliferation of synovial fibroblasts at affected joints. This produces a 
localised hypoxia and a reduced pH, both of which are capable of influencing the 
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behaviour of osteoblasts within the joint. Hypoxia inhibits Wnt signalling (discussed in 
more detail below) in osteoblasts by sequestering β-catenin to inhibit transcriptional 
activity [48]. By up-regulating Dickkopf-1 (DKK1) [49] low pH causes the down-
regulation of alkaline phosphatase synthesis in osteoblasts which prevents 
mineralisation [50].  
 
Hypoxia and acidosis also increase affect osteoclastogenesis and resorptive 
capacity. Arnett et al (2003) identified that in vitro differentiation of monocytes to 
osteoclasts (in the presence of M-CSF and RANKL) was four-fold more efficient at 
2% oxygen compared to 20% oxygen. Importantly, however, the experimental 
protocol in this instance in fact subjected the cells to repeated periods of hypoxia and 
normoxia [51] . The requirement for periods of re-oxygenation was confirmed in 
another study by Knowles and Athanasou (2009) who demonstrated that repeated 
hypoxia/reoxygenation cycles, such as those expected to occur during period of 
inflammation, enhanced osteoclast differentiation, however, when cells were 
subjected to continued hypoxia at 2% oxygen osteoclastogenesis was in fact 
dramatically inhibited [52] .In addition the resorption activity of the osteoclasts formed 
at 2% oxygen was two to fourfold higher than osteoclasts formed at higher oxygen 
tensions [51, 52] (reviewed in [53]). This combination of increased osteoclast 
formation and activity combined with a dramatic decrease in osteoblast function in 
response to hypoxia and low pH combine to drive bone destruction during 
inflammation. 
 
Cytokine-mediated bone destruction 
Pannus tissue contains large numbers of activated macrophages, leukocytes and 
FLS which release pro-inflammatory cytokines including TNFα, IL-1β, IL-6 and IL-17. 
TNFα, expressed mainly by monocytes and macrophages but also by T cells, B cells 
and FLS, plays a pivotal role in the inflamed synovial microenvironment in RA. TNFα 
is considered to be at the top of the inflammatory cascade, based on observations 
that TNFα induces the expression of other cytokines (eg. IL-1β, IL-6, IL-8) and that 
anti-TNFα treatment in RA patients significantly reduces IL-1β release by FLS [54-
56]. Moreover, in FLS, TNFα induces the production of adhesion molecules to attract 
leukocytes into the affected joints [57] as well as matrix metalloproteinases that 
destroy cartilage [58].  
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 During the last few years the impact of TNFα on bone remodelling has been 
addressed in several studies. Classically, it has been shown that this pro-
inflammatory cytokine increases the number of osteoclast precursors [59] and 
indirectly activates osteoclastogenesis by triggering RANKL release from 
lymphocytes [60, 61] and endothelial cells [62] as well as increasing RANKL and M-
CSF production by stromal cells [63, 64]. The effect of TNFα on bone erosion has 
been studied in detail using the hTNFtg [65] and the TNFΔARE [66] mouse models of 
RA. Both these models overexpress TNFα and result in osteoclast-mediated bone 
destruction in joints. TNF is known to enhance osteoclast activity directly, by 
promoting maturation of bone marrow macrophages into mature osteoclasts in the 
presence of RANK-ligand [60] [67].  
 
Stromal cells promote bone loss via interaction with immune cells 
Recent studies have shown that the interaction of RA-FLS with infiltrating immune 
cells plays a key role in both chronic inflammation and bone destruction. In particular 
CD4+ helper T cells (Th cells), the prominent T cell subset in the sublining of 
rheumatoid synovium,  express RANKL and also cytokines which have stimulatory, 
as well as inhibitory, effects on osteoclastogenesis. Th1 cells release IL-4 and IL-10 
which blocks osteoclastogenesis, whereas Th17 cells release IL-17, IL-22, RANKL, 
IL-1, IL-6 and TNFα [60, 67] which activate osteoclastogenesis directly on osteoclast 
precursors. IL-17 and IL-22 also stimulate RANKL expression in RA FLS to activate 
osteoclastogenesis, suggesting an indirect role of T-cells in bone loss via crosstalk 
with RA-FLS [68-71]. 
The first evidence that activated T-cells play an important role in bone destruction 
has been shown by Kong and colleagues in 1999 [72]. They could demonstrate that 
CD4+ T-cells produce a sufficient amount of soluble RANKL to promote 
osteoclastogenesis which subsequently induces bone loss in a model of adjuvant 
arthritis.  
 
The importance of Th17 cells and IL-17 in bone destruction is also supported by 
studies using the collagen-induced arthritis (CIA) mouse model. IL-17A-deficient mice 
developed a markedly reduced severity of CIA accompanied by less bone erosion 
and less synovial hyperplasia [73]. Therapeutic treatment with neutralizing anti-IL-
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17A antibodies significantly reduces the severity of inflammation and bone erosion in 
various RA mouse models including CIA [74], antigen-induced arthritis [75] and  
glucose-6-phosphate isomerase (G6PI)-induced arthritis [76].  
 
IL-17 is considered to be a potential osteoclastic cytokine, because it increases 
RANKL expression in osteoblasts, RA-FLS, and IL-1 and TNFα expression in 
synovial macrophages, which activates osteoclastogenesis and subsequently drives 
bone destruction. In an in vitro co-culture model with murine bone marrow cells and 
osteoblasts, treatment with IL-17 derived from synovial fluid of RA patients results in 
an increased osteoclastogenesis by an upregulation of prostaglandin E2 in 
osteoblasts [77]. Higher IL-17A concentrations were found in synovial fluid and sera 
from RA patients compared to OA patients or healthy controls [78, 79]. Therefore 
targeting IL-17 is suggested as an attractive therapeutic target in RA. IL-17 blockers 
have been evaluated and are currently being tested in clinical trials for human RA. 
However, inhibition of IL-17 did not lead to complete disease remission, so far, and 
monoclonal antibodies against IL-17 receptor seems to be ineffective in RA [80]. 
 
Wnt signalling is critical to bone homeostasis  
The Wnt signalling pathway not only controls developmental processes such as 
skeletal patterning [81, 82], but is also crucial for maintaining bone homeostasis. 
Three major branches of Wnt signalling exist: the canonical, the Ca2+-dependent 
non-canonical and the planar cell polarity signalling pathway. Of these, the canonical 
Wnt/β-catenin pathway is known to be the predominant component that impacts on 
bone remodelling. In the absence of Wnt, β-catenin forms a destruction complex 
composed of Axin, Casein Kinase 1 (CK1), Adenomatous Polyposis Coli (APC) and 
Glycogen synthase kinase 3β (GSK3β). This complex facilitates phosphorylation, 
ubiquitination and subsequently degradation of β-catenin by the proteasome. 
Activation of signalling occurs upon binding of Wnt proteins to the Low density 
lipoprotein Receptor-related Protein 5/6 (LRP5/6) receptors and Frizzled (Fz) co-
receptors on the cell surface. Dishevelled (DSH) and the destruction complex is 
recruited to the cell membrane allowing β-catenin accumulation within the cytoplasm 
and subsequent translocation into the nucleus where it activates transcription of 
specific target genes [83].  
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A strong link between the canonical Wnt/β-catenin pathway and bone homeostasis 
has been demonstrated by studying mutations of several members of the pathway. 
Mutations in Wnt proteins such as Wnt3, Wnt3a and Wnt7A/Wnt7a lead to skeletal 
malformations in humans [84, 85] and in mice [86, 87]. Moreover, loss of function 
mutations in the human LRP5 gene as well as LRP5 knockout mice are associated 
with low bone density and skeletal fragility [88, 89], whereas gain of function 
mutations in the LRP5 gene in humans and in mice lead to an increased bone 
density [90, 91]. In previous studies it has been shown that the high bone mass 
caused by LRP5 mutations is associated with decreased binding of the Wnt inhibitors  
Sclerostin [92, 93] and DKK1 [94]. An explanation for these observed phenotypes 
could be the influence of Wnt/-catenin signalling on the regulation of the 
OPG/RANKL ratio. Recent findings have shown that the Wnt/β-catenin pathway in 
osteoblasts inhibits osteoclastogenesis through downregulation of RANKL 
expression and upregulation of OPG expression, leading to an altered OPG/RANKL 
ratio [11, 95]. Therefore, the Wnt/β-catenin pathway not only affects cell 
differentiation into mature osteoblasts and bone renewal, but also arrests bone 
degradation by blockade of RANK-RANKL interaction through OPG .  
 
 
Wnt signalling in RA 
The role of Wnt signalling in RA is not yet fully understood. β-catenin expression was 
found to be elevated in synovial tissues and FLS from RA patients compared to those 
from OA patients [96]. Several years ago, Sen and colleagues revealed that Wnt1-
mediated Wnt/β-catenin signalling is constitutively active in RA-FLS leading to pro-
MMP3 secretion and fibronectin expression. However, Wnt1 not only activates the 
canonical Wnt pathway but also the non-canonical Wnt/Ca2+ (β-catenin and LRP5/6 
independent) pathway. Wnt1 and Wnt5a initiate the non-canonical signalling cascade 
by binding to Fz co-receptor causing intracellular Ca2+ release, activation of the 
calcium sensitive enzymes calmodulin kinase II (CamKII) and protein kinase C 
(PKC). These kinases activate several transcription factors such as NFAT, NF-κB 
and AP-1 [97]. The same authors demonstrated that Wnt5a/Fz-5 non-canonical 
signalling increased IL-6, IL-8, IL-15 and RANKL release, indicating that the non-
canonical Wnt pathway might also be important for RA-FLS activation [98, 99]. These 
observations suggest that constitutive activation of canonical and/or non-canonical 
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Wnt signalling in RA-FLS may promote synovial inflammation, pannus formation and 
bone/cartilage erosion during RA.  
 
 
Wnt antagonists released by stromal cells under inflammatory conditions 
control bone remodelling 
 
A number of extracellular Wnt antagonists provide fine-tuning of the Wnt signalling 
cascade. Secreted glycoproteins such as Sclerostin and DKK1 bind to LRP5 and 
LRP6 to antagonise canonical Wnt signalling, leading to inhibition of bone formation. 
Loss of Wnt inhibitor Sclerostin expression results in high bone mass and strength in 
patients with sclerosteosis [100] and Van Buchem disease [101] as well as in 
Sclerostin deficient mice [102].   
 
Knowledge that the Wnt/β-catenin pathway regulates bone formation and 
degradation has sparked tremendous interest in the last decade. In particular the use 
of anti-Sclerostin antibodies in osteoporosis in which loss of Sclerostin enhances 
bone mineral density seems to be very promising. Since Wnt signalling is required for 
bone formation it was assumed that the enhanced production of Wnt-antagonists in 
the inflamed joints was responsible for the lack of bone repair seen in RA joints, 
hence, blocking Wnt-antagonists could be a promising approach to re-activate the 
Wnt pathway and counteract bone destruction. However, in reality the situation in 
vivo is more complicated.  
 
Surprisingly, antibody-mediated blockade of Sclerostin in the hTNFtg mouse model 
of RA caused an unexpected acceleration of bone erosion. Moreover, loss of 
Sclerostin in the partially TNF-dependent G6PI mouse model of arthritis had no effect 
on the progression of RA. Disease severity was ameliorated  with loss of Sclerostin in 
the K/BxN serum transfer model, which is TNF receptor independent. Combined, 
these data suggest a specific role for Sclerostin in TNFα signalling-induced bone 
erosions. Sclerostin has a protective function in TNF-dependent but not TNF-
independent inflammatory arthritis: the more inflammation is driven by TNF the 
higher the protective effect of Sclerostin [103]. In line with this data, several 
publication have shown that inhibition of Sclerostin has either no effect or a 
destructive effect on cartilage and bone: In the CIA model of RA, Sclerostin inhibition 
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had no effect on the improvement of focal bone destruction [104] and 
pharmacological inhibition of Sclerostin in a rat model of osteoarthritis showed no 
effect on inflammatory cartilage remodelling [105]. Of note, one study reported that 
increased chondrocyte Sclerostin is chondroprotective in a sheep model of 
osteoarthritis [106] and Bouzis et al found that loss of Sclerostin promotes OA in 
mice [107]. However, there has been a report that anti-Sclerostin therapy is 
protective in TNF-driven arthritis [108]. The protective effect was largely seen when 
arthritic mice were co-treated with blocking TNF antibodies, which is in line with the 
notion that TNF triggers bone loss. Clearly, there is complexity in the function of 
Sclerostin as uncovered by the animal models of RA described above and this 
should be carefully considered when using anti-Sclerostin antibodies in patients with 
RA or other TNF-dependent immune-mediated inflammatory diseases.  
 
Although, Sclerostin and DKK1 are both Wnt-inhibitors that bind LRP receptors and 
are upregulated in response to TNFα, they exhibit very different effects on bone 
under inflammatory conditions compared to non-inflammatory conditions (as seen in 
most osteoporosis situations). Diarra and co-workers have demonstrated that anti-
Dkk1 treatment in arthritic mice is able to reverse the pattern of bone destruction to 
promote activation of bone repair resulting in new bone and osteophyte formation 
[109]. To explore the role of DKK1 in RA patients Juarez et al. took synovial 
fibroblasts from treatment-naive patients with undifferentiated inflammatory arthritis of 
less than 3 months duration. Fibroblasts from patients that would subsequently be 
diagnosed with RA expressed significantly higher levels of Dkk1 messenger RNA 
and protein compared to fibroblasts from patients whose arthritis resolved. In co-
cultures with lymphocytes, more DKK1 was secreted by RA fibroblasts than by 
fibroblasts from non-inflamed joints or resolving arthritis and the levels of Dkk1 
secretion during co-culture positively correlated with lymphocyte adhesion [110]. 
Recently, Seror et al [111] found increased DKK1 levels in a cohort of early RA 
patients with enhanced bone destruction. Therefore, together with findings from 
those of the RA mouse model in which anti-DKK1 antibodies were successfully used 
to enhance bone formation, blocking DKK1 could provide a new therapeutic target for 
treating bone loss.  
 
 
This article is protected by copyright. All rights reserved.
Not all stromal cells are created equal!  
Fibroblasts, despite being the most ubiquitous stromal cells in the synovium, have 
proven difficult to characterize in molecular terms and it is only relatively recently that 
fibroblast-specific markers have been identified to allow the identification of fibroblast 
subsets. Clearly, as has been described above, there are differences between the 
phenotypes of FLS and RA-FLS, however it is becoming apparent that greater 
complexity exists than simply between disease and healthy synovial fibroblasts. Key 
fibroblast-specific markers identified so far include Fibroblast Activation Protein 1 
(FAP1), Endosialin (CD248), Vascular Cell Adhesion Molecule 1 (VCAM-1) and 
Podoplanin (GP38). The identification of these markers has allowed us to begin to 
differentiate between RA-FLS subsets and investigate their function.  
 
In 2016 Croft et al assessed the functional differences between two of these disease 
subsets: Podoplanin+ fibroblasts, which predominate in the RA synovial lining layer, 
and endosialin+ fibroblasts that are restricted to the sublining. Using a human 
cartilage and RA-FLS graft in SCID mice they showed that it is the podoplanin+ RA 
synovial fibroblast subset that is migratory and invasive [112]. A recent publication 
has also confirmed the assumption that FAP plays a crucial role in inflammatory 
destructive arthritis. FAP deletion in a mouse model of RA ameliorates cartilage 
degradation and isolated FLS from these mice show a lower cartilage adhesion 
capacity. These findings pointing to a previously unknown function of FAP in the 
attachment of FLS to cartilage during RA [113]. Taken together, these data match 
with similar findings of podoplanin+ cancer-associated fibroblasts (CAFs) promoting 
metastasis [114] and FAP+ fibroblasts promoting tumor growth in a mouse xenograft 
model [115] and suggest that targeting a specific fraction of the stromal cells may be 
an appropriate therapeutic strategy in inflammation as well as cancer. 
 
The importance of osteocytes in bone remodelling 
Other predominant cell types in the synovial joint are the osteoblast and the bone-
embedded osteoblast termed the osteocyte. Until relatively recently osteocytes were 
ignored due to difficulties isolating them from tissue and maintaining their phenotype 
ex vivo. However in the last few years improvements in techniques have allowed 
researchers to interrogate their function during bone disease. Osteocytes are 
descendants of matrix-producing osteoblasts. They are embedded in the bone matrix 
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but are not passive cells in bone behaviour, rather they act on bone remodelling 
through regulation of both osteoclast and osteoblast activity. It has been reported that 
osteocytes are able to release RANKL as well as M-CSF to recruit osteoclast 
progenitors to sites of remodelling, supporting the generation of functional resorbing 
osteoclasts [116]. It has generally been believed that osteoblasts and stromal cells 
are the main source of RANKL, however, co-culture studies from Nakashima et al. 
[117] demonstrated that purified osteocytes have a greater capacity to support 
osteoclastogenesis than osteoblasts and bone marrow stromal cells. Osteocytes not 
only communicate with osteoclasts but also with osteoblasts through the release of 
the canonical Wnt/-catenin Sclerostin, which negatively regulates osteoblast 
differentiation [118, 119]. 
 
Although osteocytes communicate with both osteoblasts and osteoclasts to produce 
RANKL and Sclerostin the question remains how RANKL and Sclerostin reach the 
bone surface, from deep within the bone. During their embedding phase, osteocytes 
form dendritic extensions (40-100 per cell) [120] to build a lacuna-canalicular 
network, maintaining connections with the bone surface and the vascular space 
[118]. Recently, Honma and co-workers [121] developed a novel co-culture system 
using osteoclast precursors together with osteocytes, embedded in a collagen gel. 
On the basis of this system, they clearly demonstrated that the osteocytic, 
membrane–bound form of RANKL communicates directly with osteoclast precursors 
through osteocyte dendritic extensions. 
 
The importance of osteocytes has been reported in many musculoskeletal diseases. 
Decreased connectivity between the osteocytes occurs in osteoporotic and 
osteoarthritic bones. Moreover bones taken from patients with osteoporosis display 
also disorientation of the dendrites [122]. Xiong et al. [123] reported that mice with 
osteocyte-specific RANKL deletion develop postnatal osteopetrosis. Recently it has 
been reported that osteocytes are associated with bone loss in inflammatory bowel 
disease in rodents (IBD) [124]. Another study revealed that patients with Crohn´s 
disease possess increased osteocyte apoptosis and reduced bone mass and bone 
formation [125]. 
Currently, the function of osteocytes and the control of osteocytogenesis under                                                                                          
inflammatory conditions in RA is not well understood. Recently, Pathak et al reported 
This article is protected by copyright. All rights reserved.
that in vitro stimulation of osteocytes with serum from RA patients results in 
enhanced osteocyte-to-osteoclast communication. They found that RA serum 
containing inflammatory cytokines enhances the RANKL/OPG ratio in osteocytes, 
which subsequently leads to enhanced osteoclastogenesis and bone destruction 
[126].  
However nothing is known so far about changes in connectivity and orientation of 
osteocytes under inflammatory conditions. It is well known that chronic inflammation 
is a major risk factor for systemic bone loss leading to osteoporosis. Even in chronic 
inflammatory diseases such as RA, local bone erosions are typically associated with 
systemic bone loss. As already discussed above, osteoporosis patients seems to 
have a decreased connectivity and disorientation of dendritic extensions in their 
osteocyte network. Therefore, it can be assumed that the osteocyte network in bones 
of RA patients might be altered, which could influence signalling molecules involved 
in bone remodelling processes. This is a relatively new area of research, however  
the influences of inflammatory factors in RA on osteocyte-mediated systemic bone 
loss has yet to be thoroughly investigated. 
 
Conclusion 
Bone loss is a common feature of a variety of musculoskeletal disorders. Under 
inflammatory conditions such as RA, the main trigger of articular bone erosion is 
synovitis, including the production of inflammatory cytokines and RANKL, leading to 
activation of osteoclastogenesis. Both activation of bone destroying osteoclasts and 
a lack of compensatory bone repair mechanisms contribute to a progressive loss of 
joint structure in RA patients. 
In this review we have explored the role of stromal cells and their influence in bone 
remodelling. Emerging data obtained have provided evidence that stromal cells are 
more than just structural cells. Under chronic inflammation they aquire novel features 
which are important for the development of pathologic processes. Knowledge of 
stromal cells and their influence in bone formation and bone destruction will facilitate 
the development of future therapeutic strategies for repair of bone erosion.  
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 Figure Legend 
 
Fig. 1:  The role of FLS in inflammatory bone destruction.  
Under healthy conditions there is a balance between bone formation and bone 
destruction to replace old bone tisssue and to repair bone defects. In RA, more bone 
is degraded by osteoclasts than created by osteoblasts, shifting the balance towards 
bone destruction. During inflammation stromal FLS, located in the synovial 
membrane of the joint space, are able to influence this balance directly or indirecly.  
FLS release RANKL in response to inflammatory cytokines such as TNFα which 
subsequently stimulates osteoclastogenesis directly. They also communicate with T 
cells or release inhibitors of bone formation such as sclerostin and DKK1. In contrast 
to DKK1, Sclerostin not only blocks osteoblast differentiation but also inhibits 
specifically TNF-mediated bone destruction, suggesting a protective effect in TNF- 
mediated bone loss. Other factors released by FLS such as myostatin directly 
activates bone destruction. Different subsets of FLS, especially gp38+ and FAP+ 
expressing FLS are highly migratory and invasive and seems to be important for 
cartilage and bone destruction. 
 
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
